Bicycle Therapeutics PLC
NASDAQ:BCYC

Watchlist Manager
Bicycle Therapeutics PLC Logo
Bicycle Therapeutics PLC
NASDAQ:BCYC
Watchlist
Price: 8.1 USD 0.62% Market Closed
Market Cap: 560.5m USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+6%
Revenue
Forecast
+4%
Operating Income
Forecast
+222%
Net Income
Forecast
+471%

Wall Street
Price Targets

BCYC Price Targets Summary
Bicycle Therapeutics PLC

Wall Street analysts forecast BCYC stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BCYC is 27.11 USD with a low forecast of 13.13 USD and a high forecast of 50.4 USD.

BCYC Lowest Forecast
Wall Street Target
13.13 USD
62% Upside
BCYC Average Forecast
Wall Street Target
27.11 USD
235% Upside
BCYC Highest Forecast
Wall Street Target
50.4 USD
522% Upside
Lowest
Price Target
13.13 USD
62% Upside
Average
Price Target
27.11 USD
235% Upside
Highest
Price Target
50.4 USD
522% Upside
Bicycle Therapeutics PLC Competitors:
Price Targets
4974
Takara Bio Inc
39% Upside
CRSP
CRISPR Therapeutics AG
121% Upside
IDYA
IDEAYA Biosciences Inc
182% Upside
L
LYTIX
Lytix Biopharma AS
79% Upside
4974
Takara Bio Inc
39% Upside
CRSP
CRISPR Therapeutics AG
121% Upside
IDYA
IDEAYA Biosciences Inc
182% Upside
L
LYTIX
Lytix Biopharma AS
79% Upside
BCRX
BioCryst Pharmaceuticals Inc
69% Upside
ASMB
Assembly Biosciences Inc
156% Upside
1167
Jacobio Pharmaceuticals Group Co Ltd
57% Downside
NIOX
Niox Group PLC
24% Upside

Revenue
Forecast

Revenue Estimate
Bicycle Therapeutics PLC

For the last 7 years the compound annual growth rate for Bicycle Therapeutics PLC's revenue is 50%. The projected CAGR for the next 3 years is 40%.

50%
Past Growth
40%
Estimated Growth
Estimates Accuracy
-7%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Bicycle Therapeutics PLC

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Bicycle Therapeutics PLC

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-62%
Average Miss
What are analyst estimates?

See Also

Summary
BCYC intrinsic value, competitors valuation, and company profile.
DCF Valuation
BCYC stock valuation using Discount Cash Flow valuation method.
Relative Valuation
BCYC stock valuation using valuation multiples.
Wall Street Estimates
BCYC price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
BCYC stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is BCYC's stock price target?
Price Target
27.11 USD

According to Wall Street analysts, the average 1-year price target for BCYC is 27.11 USD with a low forecast of 13.13 USD and a high forecast of 50.4 USD.

What is Bicycle Therapeutics PLC's Revenue forecast?
Projected CAGR
40%

For the last 7 years the compound annual growth rate for Bicycle Therapeutics PLC's revenue is 50%. The projected CAGR for the next 3 years is 40%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 256,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.